- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00974337
Relative Adrenal Insufficiency in Preterm Very Low Birth Weight Infants With Shock
Basal and Stimulated Cortisol Levels in Preterm Very Low Birth Weight Infants With and Without Shock: A Cross-sectional Study
Study Overview
Status
Conditions
Detailed Description
Till date, no studies are available that have evaluated the incidence of relative adrenal insufficiency in preterm very low birth weight (VLBW) infants with shock. The focus had been on stable preterm and critically ill preterm infants. Given that steroid treatment improves blood pressure and stabilizes cardiovascular status in preterm infants with volume and pressor-resistant hypotension,it becomes essential to examine the incidence of adrenal insufficiency in this cohort (rather than a broad group of critically ill preterm infants). Moreover, there are no studies on adrenal function in Indian neonates.
The purpose of this study is to compare the levels of basal and stimulated (using low dose [1µg/k] ACTH) cortisol levels in preterm (28-34 weeks gestation) very low birth weight (birth weight 750 gm to 1500 gm) infants with shock in the first week of life requiring vasopressor therapy and matched (gestation, birth weight, postnatal age-matched) hemodynamically stable infants ('control group').
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110029
- All India Institute of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All preterm (28 to 34 week gestation) very low birth weight (birth weight 750-1500grams.) infants born at AIIMS would be eligible for enrollment in the study. Of these infants, those who meet the following criteria would be enrolled.
- Cases: Preterm (28 to 34 week gestation) infants with birth weight between 750 and 1500 grams with shock in the first week of life requiring vasopressor therapy (dopamine or dobutamine or both in a dose of > 10 mcg/kg/min)
- Controls: Stable preterm (28 to 34 week gestation) infants with birth weight between 750 and 1500 grams who are matched for gestational age, birth weight, postnatal-age.
Exclusion Criteria:
- Major congenital malformations
- Mother receiving anticonvulsant / anti-tubercular drugs (rifampicin, isoniazid)
- Postnatal corticosteroid treatment
- Refusal to give consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Shock
Preterm VLBW infants with shock (BP <3rd centile for gestation and birth weight with at least one of the following:
|
|
No shock
Hemodynamically stable infant with normal blood pressure, capillary refill time, and urine output
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Baseline cortisol
Time Frame: At enrollment
|
At enrollment
|
|
Stimulated cortisol (after ACTH stimulation)
Time Frame: 30 minutes after ACTH stimulation
|
30 minutes after ACTH stimulation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Survival till discharge or day 28 of life
Time Frame: Until discharge or 28 days of life
|
Until discharge or 28 days of life
|
|
Chronic lung disease (CLD)
Time Frame: 36 weeks postmenstrual age
|
36 weeks postmenstrual age
|
|
Sepsis
Time Frame: until 28 days of life
|
until 28 days of life
|
Collaborators and Investigators
Investigators
- Study Chair: Vinod K Paul, MD PhD, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
- Principal Investigator: Suman Sarkar, MBBS, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
- Study Chair: Mari J Sankar, MD DM, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
- Study Chair: Ramesh Agarwal, MD DM, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-123/2008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adrenal Insufficiency
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingGlucocorticoid-induced Adrenal InsufficiencyFrance
-
University Hospital TuebingenCompletedAdrenal InsufficiencyGermany
-
Tobias ElseCorcept TherapeuticsTerminatedMifepristone | Central Adrenal InsufficiencyUnited States
-
Assistance Publique Hopitaux De MarseilleTerminatedAdrenocortical InsufficiencyFrance
-
Diurnal LimitedCompletedPrimary Adrenal InsufficiencyGermany, United Kingdom
-
University of Roma La SapienzaCompletedSecondary Adrenal Insufficiency | Primary Adrenal InsufficiencyItaly
-
Chronic Obstructive Pulmonary Disease Trial Network...Rigshospitalet, DenmarkCompleted
-
Bruno AllolioCompletedPrimary Adrenal InsufficiencyGermany
-
University of BergenKarolinska Institutet; Charite University, Berlin, GermanyActive, not recruitingPrimary Adrenal InsufficiencyNorway, Germany, Sweden
-
University Medical Center GroningenCompletedAdrenal InsufficiencyNetherlands